The aim of the study was to design and formulate an antibody-mediated targeted,
biodegradable polymeric drug delivery system releasing drug in a controlled manner to …

Breast cancer, up-regulated with human epidermal growth factor receptor type-2 (HER-2)
has led to the concept of developing HER-2 targeted anticancer therapeutics. Docetaxel …

Codelivery of chemotherapeutic drugs in nanoparticles can enhance the therapeutic effects
against tumors. However, their anticancer properties and physiochemical characteristics can …

Background We report the development of an efficient antibody delivery system for the
incorporation of trastuzumab (TZ) into poly (lactic-co-glycolic) acid nanoparticles (PLGA …

Abstract Treatment options for multidrug-resistant breast cancer are limited and ineffective.
Few combinations of chemotherapeutic agents are clinically successful in treating multiple …

The present study highlights the beneficial synergistic blend of anticancer drug paclitaxel
(PTX) and thymoquinone (TQ) in MCF-7 breast cancer cells. We aimed to augment the …

Background The objective of this study was to develop pegylated poly lactide-co-glycolide
acid (PLGA) immunonanocarriers for targeting delivery of docetaxel to human breast cancer …

Paclitaxel is one of the most effective chemotherapeutic drugs ever developed and is active
against a broad range of cancers, such as lung, ovarian, and breast cancers. Due to its low …

This study aimed at development of poly (lactic-co-glycolic acid)(PLGA) nanoparticles
embedded with paclitaxel and coated with hyaluronic acid (HA-PTX-PLGA) to actively target …

Advanced breast cancer is known to be highly evasive to conventional therapeutic regimes
with a 5-year survival rate of less than 30% compared to over 90% for early stages. Although …